EICHORCondition: Lung Cancer · Non-small Cell Lung Cancer · Sponsor: Sichuan University
This phase II study aims to evaluate the efficacy and safety of low-dose radiation + SBRT + Tislelizumab plus platinum-based chemotherapy as neoadjuvant therapy for stage II-III non-small cell lung cancer.
This description comes directly from the study's public registry record.
Jianxin Xue, MD. Phd · 18982251798 · killercell@163.com
You Lu, MD. PhD · +86 189 8060 1763 · radyoulu@hotmail.com
Always discuss trial participation with your own doctor first.
| West China Hospital of Sichuan University | Chengdu, China, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06877299